Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Leukemia

Volumn 30, Issue 7, 2016, Pages 1606-1609

  Chen, Z ^a,b   Cortes, J E ^a   Jorgensen, J L ^a   Wang, W ^a   Yin, C C ^a   You, M J ^a   Jabbour, E ^b   Kantarjian, H M ^b   Medeiros, L J ^a   Hu, S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; FEMALE; HUMAN; KARYOTYPE; LETTER; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; OVERALL SURVIVAL; PRIORITY JOURNAL; ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BLAST CELL CRISIS; DISEASE EXACERBATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLAST CRISIS; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; YOUNG ADULT;

EID: 84958817965     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.6     Document Type: Letter

References (15)

1. Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis. Blood 2012; 120: 761-767.
2. Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-Term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118: 6760-6768.
3. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002; 107: 76-94.
4. Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller MC, et al. Clonal evolution and blast crisis correlate with enhanced proteolytic activity of separase in BCR-ABL b3a2 fusion type CML under imatinib therapy. PloS One 2015; 10: e0129648.
5. Gambacorti-Passerini C, Piazza R. How I treat newly diagnosed chronic myeloid leukemia in 2015. Am J Hematol 2015; 90: 156-161.
6. Hochhaus A. Educational session: Managing chronic myeloid leukemia as a chronic disease. Hematology Am Soc Hematol Educ Program 2011; 2011: 128-135.
7. Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, et al. Safety and efficacy of imatinib in CML over a period of 10 years: Data from the randomized CML-study IV. Leukemia 2015; 29: 1123-1132.
8. Pfirrmann M, Lauseker M, Hoffmann VS, Hasford J. Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. Ann Hematol 2015; 94: S209-S218.
9. Saussele S, Silver RT. Management of chronic myeloid leukemia in blast crisis. Ann Hematol 2015; 94: S159-S165.
10. Greulich-Bode KM, Heinze B. On the power of additional and complex chromosomal aberrations in CML. Curr Genomics 2012; 13: 471-476.
11. Zaccaria A, Testoni N, Valenti AM, Luatti S, Tonelli M, Marzocchi G, et al. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. Cancer Genet Cytogenet 2010; 199: 76-80.
12. Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, et al. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood 2015; 126: 1699-1706.
13. Hehlmann R. How I treat CML blast crisis. Blood 2012; 120: 737-747.
14. Radich JP. The biology of CML blast crisis. Hematology Am Soc Hematol Educ Program 2007, 384-391.
15. Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma 2014; 55: 1451-1462.